Incyte to acquire Vega Therapeutics for $2B, expanding into bleeding disorder treatments.

Incyte Corporation will acquire Vega Therapeutics for up to $2 billion to expand its portfolio into bleeding disorder treatments, including a late-stage drug candidate for von Willebrand disease. Analyst firm Oppenheimer maintained a "Perform" rating on Incyte, indicating expected market-aligned stock performance. The stock is currently fairly valued, trading near $101 per share, with significant price movement over the past year. This acquisition could broaden Incyte's presence in blood-related therapies and potentially introduce a new preventative treatment for bleeding disorders.